RT Journal Article
SR Electronic
T1 Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.04.21265908
DO 10.1101/2021.11.04.21265908
A1 Wanlapakorn, Nasamon
A1 Suntronwong, Nungruthai
A1 Phowatthanasathian, Harit
A1 Yorsaeng, Ritthideach
A1 Vichaiwattana, Preeyaporn
A1 Thongmee, Thanunrat
A1 Auphimai, Chompoonut
A1 Srimuan, Donchida
A1 Thatsanatorn, Thaksaporn
A1 Assawakosri, Suvichada
A1 Kanokudom, Sitthichai
A1 Poovorawan, Yong
YR 2021
UL http://medrxiv.org/content/early/2021/11/05/2021.11.04.21265908.abstract
AB In light of intermittent supply shortages of individual vaccines and evidence of rare but serious adverse events after vaccination, heterologous regimens for COVID-19 vaccines have gained significant interest. This study aims to assess the reactogenicity and immunogenicity of the heterologous adenoviral vector vaccine regimen (ChAdOx1-S, AstraZeneca; hereafter referred to as AZ) and the inactivated vaccine regimen (CoronaVac; hereafter referred to as CV) regimen in healthy Thai adults immunized between June and September 2021. Our study showed that adverse events following homologous CV-CV and AZ-AZ, and heterologous CV-AZ and AZ-CV combinations, were mild and well tolerated overall. Receptor-binding domain (RBD)-specific antibody responses and neutralizing activities against wild-type and variants of concern after two-dose vaccination were higher in the heterologous CV-AZ and homologous AZ-AZ groups compared to the CV-CV and AZ-CV groups. Conversely, the spike-specific IgA response was detected only in the CV-AZ group after two doses of vaccination. The total interferon gamma response was detected in both the CV-AZ and AZ-CV groups after the two-dose vaccination. Given the shorter completion time of two doses, heterologous CoronaVac followed by ChAdOx1-S can be considered as an alternative regimen to homologous efficacy-proven ChAdOx1-S in countries with circulating variants. Additional studies on the efficacy and durability of immune responses induced by heterologous vaccine regimens are warranted.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialTCTR20210319003 TCTR20210628005Funding StatementThis work was supported by The National Research Council of Thailand (NRCT), Health Systems Research Institute (HSRI), The Center of Excellence in Clinical Virology of Chulalongkorn University, and King Chulalongkorn Memorial Hospital.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocols were approved by the Institutional Review Board (IRB) of the Chulalongkorn University Faculty of Medicine (IRB numbers 192/64 and 491/64). Written informed consent was obtained from all participants prior to collecting clinical data and samples. This study is conducted in accordance with the Helsinki Declaration of 1975.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.